Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 285 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sutent Clear all
Terminated Phase 2 Interventional Results available

Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery

NCT02315625
View directory record Official record
Conditions
Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas
Interventions
Sunitinib, Everolimus
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 2, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

NCT02761057
View directory record Official record
Conditions
Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Crizotinib, Savolitinib, Sunitinib Malate
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
586
States / cities
Anchorage, Alaska • Kingman, Arizona • Fort Smith, Arkansas + 361 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Sep 2, 2026, 10:53 AM EDT
Active, not recruiting Phase 3 Interventional

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

NCT05678673
View directory record Official record
Conditions
Non-Clear Cell Renal Cell Carcinoma
Interventions
XL092, Nivolumab, Sunitinib Malate
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
10
States / cities
Duarte, California • Newport Beach, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 2, 2026, 10:53 AM EDT
Completed Not applicable Interventional Results available

A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.

NCT00443534
View directory record Official record
Conditions
Neoplasms
Interventions
SU011248
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
38
States / cities
Aurora, Colorado • Littleton, Colorado • Orlando, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated May 23, 2013 · Synced Sep 2, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib

NCT00410124
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
RAD001, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
31
States / cities
Fayetteville, Arkansas • Duarte, California • Sacramento, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Sep 2, 2026, 10:53 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

NCT02811861
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Lenvatinib, Everolimus, Pembrolizumab, Sunitinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,069 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
35
States / cities
Stanford, California • Boca Raton, Florida • Fort Myers, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 2, 2026, 10:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00453154
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma
Interventions
Carboplatin, Cisplatin, Etoposide, Laboratory Biomarker Analysis, Placebo Administration, Sunitinib Malate
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
125
States / cities
Arroyo Grande, California • Castro Valley, California • Emeryville, California + 81 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 2, 2026, 10:53 AM EDT
Terminated Phase 3 Interventional Results available

Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy

NCT00676650
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Prednisone, sunitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
873 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
87
States / cities
Decatur, Alabama • Huntsville, Alabama • Anaheim, California + 73 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Sep 2, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

NCT00847015
View directory record Official record
Conditions
Bladder Cancer, Urinary Bladder
Interventions
Sunitinib, Gemcitabine, cisplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Sep 2, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional Results available

Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases

NCT00910039
View directory record Official record
Conditions
Cognitive/Functional Effects, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sunitinib malate, cognitive assessment
Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Detroit, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2014 · Synced Sep 2, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional Results available

A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma

NCT01391130
View directory record Official record
Conditions
Metastatic Clear Cell Renal Cell Carcinoma
Interventions
LY2510924, Sunitinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
21
States / cities
Scottsdale, Arizona • Norwich, Connecticut • Newark, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 2, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization

NCT00434109
View directory record Official record
Conditions
Neuroendocrine Tumor, Islet Cell Tumor
Interventions
Sunitinib malate, Hepatic Artery Embolizations
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 13, 2012 · Synced Sep 2, 2026, 10:53 AM EDT
Active, not recruiting Phase 2 Interventional

Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)

NCT00715442
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Sunitinib, Nephrectomy
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 2, 2026, 10:53 AM EDT
Terminated Phase 1 Interventional

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

NCT03878524
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
Interventions
Abemaciclib, Abiraterone, Afatinib, Bevacizumab, Bicalutamide, Biospecimen Collection, Bortezomib, Cabazitaxel, Cabozantinib, Capecitabine, Carboplatin, Celecoxib, Cobimetinib, Copanlisib, Dabrafenib, Dacomitinib, Darolutamide, Dasatinib, Doxorubicin, Durvalumab, Enasidenib, Entrectinib, Enzalutamide, Erlotinib, Everolimus, Fluorouracil, Idelalisib, Imatinib, Ipilimumab, Lenvatinib, Leucovorin, Lorlatinib, Losartan, Nab-paclitaxel, Neratinib, Nivolumab, Olaparib, Oxaliplatin, Palbociclib, Panobinostat, Pembrolizumab, Pertuzumab, Ponatinib, Quality-of-Life Assessment, Regorafenib, Ruxolitinib, Sirolimus, Sorafenib, Sunitinib, Trametinib, Trastuzumab Emtansine, Tretinoin, Vemurafenib, Venetoclax, Vismodegib, Vorinostat
Drug · Biological · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Sep 2, 2026, 10:53 AM EDT
Terminated Phase 3 Interventional

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma

NCT01582672
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma, Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions
Standard Treatment, AGS-003
Drug · Biological
Lead sponsor
Argos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
88
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • La Jolla, California + 71 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Sep 2, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

NCT02779283
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Interventions
Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Idarubicin, Idelalisib, In Vitro Kinase Inhibitor Assay, Leucovorin Calcium, Methotrexate, Methylprednisolone Sodium Succinate, Ponatinib Hydrochloride, Rituximab, Ruxolitinib Phosphate, Sorafenib Tosylate, Sunitinib Malate, Vincristine Sulfate
Drug · Device · Biological
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 64 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 25, 2020 · Synced Sep 2, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional Results available

Sunitinib in Certain Subtypes of Soft Tissue Sarcomas

NCT00859456
View directory record Official record
Conditions
Sarcoma, Soft Tissue
Interventions
Sunitinib
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Sep 2, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors

NCT00615446
View directory record Official record
Conditions
Solid Tumors
Interventions
SU011248; Gemcitabine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2010 · Synced Sep 2, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)

NCT01271712
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
Regorafenib (Stivarga, BAY73-4506), Placebo, Best supportive care
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
9
States / cities
Scottsdale, Arizona • Evanston, Illinois • Skokie, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Sep 2, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies

NCT01254864
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone Acetate, Prednisone, Sunitinib, Dasatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Sep 2, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Sunitinib for Refractory Malignant Ascites

NCT00796861
View directory record Official record
Conditions
Ascites
Interventions
Sunitinib
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Sep 2, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery

NCT00459979
View directory record Official record
Conditions
Kidney Cancer
Interventions
sunitinib malate, conventional surgery
Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Sep 2, 2026, 10:53 AM EDT
Terminated Phase 1 Interventional

CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer

NCT02074878
View directory record Official record
Conditions
Breast Cancer
Interventions
Crixotinib 200 mg and Sunitinib Cohort 1, Crixotinib 250 mg and Sunitinib Cohort 2, Crizotinib & Sunitinib 37.5 mg Cohort 3
Drug
Lead sponsor
Mothaffar Rimawi
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Sep 2, 2026, 10:53 AM EDT
Completed Phase 2 Interventional

Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment

NCT00678119
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
AGS-003, Sunitinib
Biological · Drug
Lead sponsor
Argos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
12
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2013 · Synced Sep 2, 2026, 10:53 AM EDT